Revenue
$148.87M
Fiscal year ended 2026-03-31Operating income
$49.11M
Fiscal year ended 2026-03-31Free cash flow
$22.82M
Fiscal year ended 2026-03-31ELITE PHARMACEUTICALS INC /NV/ (ELTP) reported revenue of $148.87M and net income of $44.87M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ELITE PHARMACEUTICALS INC /NV/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $148.87M | $84.04M | $56.63M | $34.16M | $32.26M | $25.38M | $17.99M | $7.57M | $7.46M | $9.64M |
| Cost of revenue | $73.85M | $43.96M | $30.27M | $17.56M | $17.47M | $13.51M | $10.02M | $4.70M | $3.51M | $5.90M |
| Gross profit | $75.02M | $40.09M | $26.36M | $16.59M | $14.80M | $11.87M | $7.98M | $2.87M | $3.95M | $3.74M |
| Operating income | $49.11M | $19.60M | $10.79M | $3.68M | $5.07M | $2.10M | -$2.29M | -$9.16M | -$9.05M | -$7.36M |
| Net income | $44.87M | -$4.31M | $20.11M | $3.56M | $8.90M | $5.09M | -$2.24M | -$9.28M | -$3.67M | $3.81M |
| Research & development | $5.74M | $7.96M | $6.88M | $6.20M | $4.05M | $5.11M | $5.53M | $7.60M | $9.62M | $8.30M |
| Weighted-average diluted shares | shares 1.14B | shares 1.07B | shares 1.02B | shares 1.01B | shares 1.01B | shares 943.00M | shares 993.26M | shares 816.31M | shares 798.17M | shares 844.51M |
| Pretax income | $56.81M | -$52.14K | $463.09K | $3.99M | $6.30M | $4.14M | -$2.24M | -$9.96M | -$4.72M | $1.94M |
| Income tax expense | $11.94M | $4.26M | -$19.65M | $424.03K | -$1.74M | Unavailable | Unavailable | -$676.02K | -$1.05M | -$1.87M |
| Diluted EPS | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 | $0.00 | $0.00 | $-0.01 | $-0.01 | $-0.01 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $17.60M | $9.00M | $7.15M | $5.12M | $4.46M | $3.32M | $3.35M | $3.08M | $2.33M | $2.08M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | Unavailable | Unavailable | $7.11M | $7.83M | $8.54M | $3.19M | $1.13M | $2.28M | $7.18M | $10.59M |
| Total assets | $138.29M | $96.39M | $83.65M | $40.90M | $35.15M | $26.19M | $24.96M | $24.40M | $30.88M | $34.31M |
| Current assets | $112.11M | $57.74M | $40.01M | $21.51M | $18.86M | $12.19M | $10.25M | $8.86M | $13.70M | $18.41M |
| Total liabilities | $39.41M | $42.87M | $26.07M | $11.94M | $9.93M | $10.04M | $14.30M | $13.01M | $12.41M | $8.65M |
| Current liabilities | $17.39M | $11.84M | $13.05M | $7.83M | $6.69M | $5.81M | $8.64M | $6.91M | $5.11M | $3.34M |
| Total equity incl. NCI | $98.88M | $53.52M | $57.58M | $28.96M | $25.22M | $16.15M | $10.66M | -$2.51M | $4.57M | $25.66M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $13.90M | $13.90M | $0 |
| Inventory | $21.26M | $16.24M | $12.93M | $9.55M | $6.74M | $5.01M | $4.14M | $4.52M | $4.90M | $6.42M |
| Accounts receivable | $59.72M | $29.21M | $19.45M | $3.09M | $3.06M | $3.50M | $4.11M | $1.32M | $675.88K | $934.06K |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | $1.24M | $1.47M | $1.58M | Unavailable | Unavailable | Unavailable |
| Accounts payable | $6.05M | $2.96M | $2.71M | $2.45M | $1.43M | $929.69K | $1.58M | $1.38M | $1.66M | $1.05M |
Cash flow
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $23.75M | $7.46M | -$3.24M | $3.34M | $6.51M | $3.19M | -$1.79M | -$6.79M | -$4.81M | -$7.88M |
| Capital expenditures | $925.63K | $1.63M | $809.65K | $5.74M | $498.57K | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | -$925.63K | -$2.40M | -$809.65K | -$5.74M | -$498.57K | -$262.78K | -$34.95K | $330.87K | -$274.85K | -$1.10M |
| Financing cash flow | -$4.32M | -$825.74K | $3.34M | $1.70M | -$667.13K | -$869.83K | $689.54K | $1.57M | $1.67M | $8.07M |
| Net change in cash | $18.50M | $4.23M | -$705.59K | -$695.72K | $5.34M | Unavailable | -$1.14M | -$4.90M | -$3.41M | -$917.49K |
| Stock-based compensation | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $1.07M | $1.23M | $1.32M | $1.28M | $1.21M | $1.31M | $1.32M | $1.26M | $996.41K | $714.53K |
Derived
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $22.82M | $5.83M | -$4.04M | -$2.40M | $6.01M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 50.4% | 47.7% | 46.5% | 48.6% | 45.9% | 46.8% | 44.3% | 37.9% | 52.9% | 38.8% |
| Operating margin | 33.0% | 23.3% | 19.1% | 10.8% | 15.7% | 8.3% | -12.7% | -121.0% | -121.4% | -76.3% |
| FCF margin | 15.3% | 6.9% | -7.1% | -7.0% | 18.6% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current ratio | 6.45x | 4.88x | 3.07x | 2.75x | 2.82x | 2.10x | 1.19x | 1.28x | 2.68x | 5.50x |
| Revenue YoY growth | 77.1% | 48.4% | 65.8% | 5.9% | 27.1% | 41.0% | 137.8% | 1.5% | -22.6% | Unavailable |
| Net margin | 30.1% | -5.1% | 35.5% | 10.4% | 27.6% | 20.0% | -12.5% | -122.6% | -49.2% | 39.5% |
| R&D / revenue | 3.9% | 9.5% | 12.2% | 18.2% | 12.6% | 20.1% | 30.7% | 100.4% | 129.0% | 86.1% |
| CapEx / revenue | 0.6% | 1.9% | 1.4% | 16.8% | 1.5% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 21.0% | Unavailable | -4242.3% | 10.6% | -27.5% | Unavailable | Unavailable | Unavailable | Unavailable | -96.1% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELTP in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-K · Filed 2026-06-29View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-K · Filed 2025-06-30View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.